Molecular Templates

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and is headquartered in Austin, TX.

AUSTIN, Texas, May  22, 2020  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced it has secured a debt financing facility for up to $45 million from K2 HealthVentures, a healthcare-focused specialty finance company. MTEM received a first tranche of $15 million upon closing, a portion of which has been used to repay the remaining indebtedness that was outstanding under the Company’s prior credit facility. Two subsequent tranches totaling up to $30 million will become available to MTEM, at its option, upon the achievement of certain milestones with respect to the second tranche and, subject to lender consent and certain additional conditions with respect to the third tranche.

Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures

As of late, it has definitely been a great time to be an investor Molecular Templates

Will Molecular Templates Continue to Surge Higher?

Artisan Partners Asset Management

BioCryst Pharmaceuticals

Calix

Orion Energy Systems

Superior Energy Services

Trinity Industries

Take advantage of panic selling with these 7 cheap stocks.

7 Great Stocks for a Small Budget

Milestone Triggers $10 Million Payment to Molecular Templates Milestone Triggers $10 Million Payment to Molecular Templates

Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma

Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships

Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

AUSTIN, Texas, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, announced today the appointment of Corazon “Corsee” Dating Sanders, Ph.D. to its board of directors, effective immediately.

Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

Magenta Therapeutics Inc

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

2 Small-Cap Biotechs That Soared Last Week

AUSTIN, Texas, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holder’s option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible preferred stock to be sold in the offering are being sold by Molecular. In addition, Molecular has granted to the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock. The offering is expected to close on or about November 25, 2019, subject to the satisfaction of customary closing conditions. The gross proceeds to Molecular from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Molecular, are expected to be $50.0 million.

Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

AUSTIN, Texas, Nov.  20, 2019  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that it has commenced an underwritten public offering of its common stock and newly designated Series A convertible preferred stock. Molecular also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by Molecular.

Molecular Templates, Inc. Announces Proposed Public Equity Offering

AUSTIN, Texas, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, announced today that it will host an analyst & investor breakfast on November 15th from 8:00am to 10:00am ET in New York City.

Molecular Templates Hosting Analyst & Investor Meeting

Shares have risen by 20% since my initial article.

Molecular Templates: Pipeline Progressing, Clinical Updates Loom

AUSTIN, Texas, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, announced today that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference, and the Cantor Fitzgerald 2019 Healthcare Conference, both taking place in New York City.

Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Molecular Templates (MTEM) to Report a Decline in Earnings: What to Look Out for

Shares have risen as a result of optimism regarding Takeda partnership and advancing ETB pipeline.

Molecular Templates: Updates To Thesis

As of late, it has definitely been a great time to be an investor Molecular Templates.

Will Molecular Templates to Surge Higher?

Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know

News for Molecular Templates Stock (MTEM)